Selexipag review found lower hospitalization odds, with other outcomes uncertain
Hospitalization odds were lower with selexipag than placebo, while the primary measure of resistance in lung blood vessels remained inconclusive.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
In the pooled trials, selexipag was associated with lower odds of hospitalization for worsening pulmonary hypertension and of serious adverse events. Resistance in lung blood vessels, the primary outcome, did not improve significantly; neither did walking distance or mortality. A lower blood biomarker level was a separate finding and does not establish longer survival.
This abstract-based explanation lacks follow-up durations and detailed treatment-related adverse-event results. Nonsignificant findings leave uncertainty about several outcomes; they do not demonstrate that selexipag and placebo have equivalent effects.
What researchers found
Hospitalization for worsening pulmonary hypertension
Selexipag hospitalization odds were 0.63 times placebo odds, indicating lower odds. This does not give an absolute risk reduction; follow-up was not reported.
The main outcome stayed uncertain
Pulmonary vascular resistance measures resistance in blood vessels in the lungs and was the review's primary outcome. Its inconclusive result means improvements in other outcomes should be considered separately, rather than generalized across measures.
A blood marker is distinct
NT-proBNP levels decreased with selexipag, while the mortality comparison was not statistically significant. A change in this blood marker does not, by itself, establish that patients lived longer or explain the hospitalization finding.
The original publication
Efficacy and Safety of Selexipag in Pulmonary Hypertension: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Alowami M, Ch'ng BX, Babasola RO et al.
Cardiol Rev · 2026
- PubMed ID
- 41703674
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.